Hereditary AngioEdema, Neurobiology and Psychopathology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

35 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-11-30

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Since 1963 Hereditary AngioEdema (HAE) is considered an autosomal dominant disorder (Donaldson and Evans), characterized by a quantitative and/or qualitative deficit of C1 esterase inhibitor (C1-INH), which affects approximately 1:50.000 individuals in the general population. From this period the link between HAE and psychiatry was interrupted, however genetic issues could not comprehensively explain the clinical evolution of the disease. Clinical studies show an evident gap between genotype and phenotype of HAE. For this still controversial question, we have designed this cross-sectional study in order to establish the relationship between HAE clinical manifestations and neurobiological/psychopatological parameters.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Autonomic Nervous System Profile in Hereditary Angioedema

NCT06408805

Hereditary Angioedema

COMPLETED

A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema

NCT07293364

Hereditary Angioedema (HAE)

NOT_YET_RECRUITING NA

C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)

NCT00292981

Hereditary Angioedema

COMPLETED PHASE3

A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt

NCT07218393

Hereditary Angioedema (HAE)

NOT_YET_RECRUITING

Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks

NCT00168103

Hereditary Angioedema

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hereditary AngioEdema Anxiety Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HereditaryAngioEdema

Patients from the Eastern Sicily HAE register

Clinical and psychopathological assessment of HAE patients

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clinical and psychopathological assessment of HAE patients

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Diagnosis of HAE

Exclusion Criteria

* Current pharmacological treatment including ACE-inhibitors, ACE inhibitors, glucocorticoids, oestroprogestative, psychotropic drugs, drugs acting on the immune system (15 days before), anesthetics (in the previous three months).
* Inflammation / infection (eg, chronic inflammatory diseases, acute) in the last 15 days.
* Ongoing allergies.
* Night work over the past 15 days.
* Vigorous physical activity or alcohol consumption (the day before the assessment).
* Women in follicular phase of menstrual cycle.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No